Picture of Herbalife logo

HLF — Herbalife News Story

0.000.00%
us flag iconLast trade - 00:00
Consumer DefensivesAdventurousMid CapContrarian

Herbalife Q2 adjusted EPS misses estimates on FX headwinds

Herbalife Q2 adjusted EPS misses estimates on FX headwinds


Overview

  • Nutrition products seller's Q2 net sales rose 5.4% yr/yr, beating analyst expectations

  • Adjusted EBITDA for Q2 beat analyst expectations

  • Company to transition CFO at year-end, with Scott Schaefer named successor


Outlook

  • Herbalife sees Q3 net sales up 0.5% to 4.5% YoY, adjusted EBITDA of $160 mln to $180 mln

  • Company narrows 2026 adjusted EBITDA guidance to $670 mln to $690 mln, citing FX headwinds

  • Herbalife expects 2026 capital expenditures of $50 mln to $70 mln and SaaS costs of $35 mln to $55 mln


Result Drivers

  • NEW PRODUCT LAUNCHES - Co said the launch of Bioniq GO and other new products in Europe and the U.S. contributed to topline growth

  • REGIONAL PERFORMANCE - Strong sales growth in Asia Pacific and Latin America offset declines in EMEA and China

  • FX HEADWINDS - Co said foreign exchange negatively impacted reported net sales and adjusted EBITDA

  • GROSS MARGIN PRESSURE - Gross profit margin declined due to sales mix, higher costs, and inventory write-downs, partly offset by pricing benefits


Company press release: ID:nBwb3G53ta


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Sales

Beat

$1.33 bln

$1.31 bln (3 Analysts)

Q2 Adjusted EPS

Miss

$0.51

$0.54 (2 Analysts)

Q2 Loss Per Share

$0.25

Q2 Net Loss

$26.30 mln

Q2 Adjusted EBITDA

Beat

$166.60 mln

$158.98 mln (3 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the food processing peer group is "buy"

  • Wall Street's median 12-month price target for Herbalife Ltd is $21.00, about 64.1% above its August 4 closing price of $12.80

  • The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 6 three months ago


Reuters Recommended Reads

  • Aug 4 - USANA Health Sciences Q2 sales fall amid weaker Hiya and Rise performance

  • Aug 3 - Medifast Q2 revenue falls 28% as active coaches drop

  • Aug 4 - P&G buys supplements maker Thorne for $3.8 billion as wellness push intensifies


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Herbalife

See all news